Asia/Oceania
The firm's next move will be to pit aumolertinib against AstraZeneca's Tagrisso, the new standard of care in EGFR-mutated NSCLC.
City of Hope, Imugene Begin Trial of Oncolytic Virus in Advanced Solid Cancers
The partners will see if the oncolytic virus CF33-hNIS, dubbed Vaxinia, can increase PD-L1 tumor expression and make patients responsive to Merck's Keytruda.
Avalon GloboCare, Lu Daopei Hematology Institute Partner to Develop Cell Therapy CDx
The deal, which is subject to negotiation, will help Avalon create diagnostics for personalizing its current and future cell immunotherapy programs.
It remains to be seen how precision oncology drug and genetic test developers will improve representation of racial and ethnic minorities based on the agency's guidelines.
Taiho Pharmaceutical Acquires Cullinan Pearl, Regaining Rights to EGFR Inhibitor
Taiho licensed the drug to Cullinan in 2019 but has now acquired Cullinan subsidiary Cullinan Pearl to resume codevelopment and commercialization of the program.